Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NEUROSIVIR: Inhaled Remdesivir and NA-831 in Healthy Volunteers
NCT04480333Phase 1Unknown
- Sponsor
- Biomed Industries
- Start
- Sep 2020
- Primary completion
- Dec 2020
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of remdesivir and cyclo(prolylglycyl) in coronavirus disease 2019 (COVID-19) (12 arms), sponsored by Biomed Industries. Primary endpoints: Treatment-Emergent Adverse Events at Day 30 and Treatment-Emergent Graded Laboratory Abnormalities at Day 30. Status: unknown.
02
Drugs
remdesivircyclo(prolylglycyl)
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04480333.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04480333.